Stat3 phosphorylation during graft-versus-host disease
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorBrian Betts
Life of this patent
Estimating the term…
Abstract
Compositions and methods to reduce the risk of graft versus host disease (GVHD) in a subject receiving hematopoietic stem cell transplantation (HSCT). Also disclosed are methods for identifying patients receiving HSCT who are at risk for developing GVHD, methods for prognosing the severity of GVHD in a subject receiving HSCT, and methods for monitoring efficacy of a therapeutic for treatment of GVHD in a subject HSCT.
Claims27
A method for reducing the risk of graft versus host disease (GVHD) in a subject receiving hematopoietic stem cell transplantation (HSCT), comprising administering to the subject a therapeutically effective amount of inhibitor of signal transducer and activator of transcription 3 (STAT3).
(canceled)
(canceled)
A method for identifying patients receiving hematopoietic stem cell transplantation (HSCT) who are at risk for developing graft versus host disease (GVHD), comprising assaying a biological sample from the patient for STAT3 phosphorylation within CD4+ T-cells, wherein detection of STAT3 phosphorylation in at least 48% of the CD4+ T-cells is an indication that the patient will develop GVHD.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for prognosing the severity of graft versus host disease (GVHD) or monitoring efficacy of a therapeutic for treatment of GVHD in a subject receiving hematopoietic stem cell transplantation (HSCT), comprising assaying a biological sample from the subject for detection of T-helper 17 (TH17) cells, wherein the amount of tissue-resident TH17 cells is an indication of pathological grade of GVHD in the subject, and wherein a reduction in the amount of tissue-resident TH17 cells after treatment is an indication of therapeutic efficacy.
(canceled)
(canceled)
Dependencies are inferred from the claim text.